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Summary: Lipoprotein(a) (Lp(a)) is a strong independent risk factor for premature atherosclerosis. Structurally,
Lp(a) closely resembles LDL. Its protein moiety contains apolipoprotein B-100 and apolipoprotein(a). We
evaluated two commercial enzyme immunoassays (ElAs) and an immunoradiometric assay (IRMA) for Lp(a).
The three assays differed in their design and they used different antibodies. In the immunoradiometric assay,
two different monoclonal antibodies were used. In the first EIA, monoclonal anti-apolipoprotein(a) was
bound to the solid phase and Lp(a) was detected with polyclonal anti-apolipoprotein B (Lp(a):B-EIA). In the
second EIA, polyclonal anti-apolipoprotein(a) was used as capturing antibody and as detecting antibody
(apo(a)-EIA). Ninety three plasma samples were assayed for Lp(a) with the three methods. The best correlation
was obtained between the IRMA and the Lp(a):B-EIA (r = 0.971). Correlations between the apo(a)-EIA on
the one hand and the IRMA or the Lp(a):B-EIA on the other hand were 0.889 and 0.836, respectively. The
methods significantly differed in their calibration. This resulted in different mean Lp(a) concentrations. When
tested against purified Lp(a), the apo(a)-EIA appeared accurately calibrated, whereas the IRMA and the
Lp(a):B-EIA overestimated Lp(a) by approximately twofold. In the Lp(a):B-EIA, the detecting antibody is
directed against apolipoprotein B. The Lp(a):B-EIA is, therefore, not affected by the apolipoprotein(a) size
polymorphism. This allows expression of the concentration of Lp(a):B complexes on a molar basis. In contrast,
the polyclonal antibody-based apo(a)-EIA measures the concentration of apolipoprotein(a) antigen, and may,
therefore, be susceptible to inter- and intra-individual polydispersity of apolipoprotein(a) and Lp(a) particles.
The data underline that both design and calibration of Lp(a) immunoassays are crucial.
Introduction
 A .. 4 · / \ · u -^Apolipoprotem(a) is homologous with plasmmogen
Lipoprotein(a) (Lp(a)) is an LDL^like particle. Its (23 — 25). This has stimulated speculation that Lp(a)
protein moiety consists of apolipoprotein B and apo- has an inhibitory role in fibrinolysis (26). Apolipo-
lipoprotein(a) which are linked by a disulphide bond protein(a) contains a variable number of plasminogen"
(1 — 5). There is ample evidence that Lp(a) is a strong kringle 4-type units, and one copy of each a kringle
independent predictor for coronary artery disease 5 and a protease-like domain. Due to variations in
(6 — 11), stroke (12,13), and retinal vascular occlusion the number of kringle 4-type repeats (27), apolipo-
(14). This has raised the demand for convenient and protein(a) displays size polymorphism (28, 29). The
reliable means of quantifying Lp(a). So far, Lp(a) has relative masses of the apolipoprotein(a) isoforms
been measured by a variety of methods such as radial range from 400000 to MT 700000. Because the
immunodiffusion (15), electroimmunoassay (6, 16), kringle 4-type repeats share a high degree of homol-
zone immunoelectrophoresis (16), nephelometry (17), ogy, apolipoprotein(a) is expected to contain a large
radioimmunoassay (18), and enzyme immunoassays number of 'repetitive' epitopes. Therefore, depending
(19—22). on the assay type and antibody specificity, the size
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polymorphism of apolipoprotein(a) may influence the
measurement of Lp(a).
We here present results of a comparison of three
commercial methods for the determination of Lp(a).
The first method was an immunoradiometric assay
(IRMA), based on two monoclonal antibodies rec-
ognizing apolipoprotein(a). The second method was
an enzyme immunoassay (ElA), in which monoclonal
anti-apolipoprotein(a) was used as capturing anti-
body, and detection was carried out with polyclonal
anti-apolipoprotein B. The third method was also an
EIA, which made use of polyclonal anti-apolipopro-
tein(a) as capturing as well as detecting antibody.
Materials and Methods
Two site immunorad iome t r i c assay
for apolipoprotein(a)
Antibodies and reagents were obtained as components of a test
kit from Pharmacia Diagnostics AB (Uppsala, Sweden). The
assay was carried out according to the instructions of the
supplier. It uses two monoclonal antibodies in excess. During
one-step incubation, apolipoprotein(a) reacts with the capturing
antibody (cl 280) coated to Sepharose-particles, as well as with
the 125I-labelled tracer (cl 356). The antigen/antibody sandwich
is then separated from excess tracer by centrifugation and
decantation, and the radioactivity in the pellet is counted. The
assay was calibrated using standards provided with the kit.
Results are reported in U/l. According to the manufacturer,
U/l should correspond to mg/1 Lp(a).
Enzyme immunoassays
Two non-competitive enzyme immunoassays were used. In the
first EIA, Lp(a) reacts with monoclonal anti-apolipoprotein(a)
on the solid phase and is then detected with polyclonal anti-
apolipoprotein B. This method will be referred to as Lp(a):B-
EIA. Reagents and microwell plates required for the Lp(a): B-
EIA were purchased from Byk Sangtec Diagnostika (Dietzen-
bach, Germany). The measurements were performed according
to the manufacturer's instructions. In the second EIA, poly-
clonal anti-apolipoprotein(a) was used as the capturing anti-
body, and peroxidase-labelled anti-apolipoprotein(a) was used
as the detecting antibody. This assay was obtained from Im-
muno Diagnostika (Heidelberg, Germany). It will be referred
to as apo(a)-EIA. Each EIA was calibrated using standards
provided by the manufacturer. Absorbances were read on a
Titertek MCC 340 microplate reader (Flow Laboratories). All
EIAs were run in duplicate.
Plasma samples
Analyses were carried out in specimens from outpatients re-
ferred to the Frankfurt University Hospital for lipoprotein
analysis. Blood was drawn into tubes containing EDTA - K2(final concentration: 1.5-2 g/1). Plasma was recovered by cen-
trifugation. Samples were stored at — 20 °C, on average, for
one, seven, and eight weeks before they were analysed with the
IRMA, the apo(a)-EIA, and the Lp(a):B-EIA, respectively.
Maximum storage times were 3 weeks, 16 weeks, and 17 weeks
for the IRMA, the apo(a)-EIA, and the Lp(a):B-EIA, respec-
tively. Previous studies in which samples with intermediate and
high Lp(a) concentrations were stored at —20 °C for four weeks
showed that none of the methods was significantly affected by
freezing and thawing.
Purification of Lp(a)
Lp(a) was prepared from the regenerate fluid of a dextran
sulphate-based LDL-apheresis system (Kanegafuchi MA 01 -
Liposorber LA 15) by sequential ultracentrifugatiori (1.050 kg/1
and 1.125 kg/1) and gel filtration (30).
Electrophoretic methods
SDS-PAGE (T = 5%, C = 2.7%) was run in a BioRad Mini
Protean II cell using the buffer system of Laemmli (31). The
samples were prepared by mixing ΙΟμΙ plasma, 50 μΐ electro-
phoresis buffer (containing 40 g/1 sodium dodecyl sulphate
(SDS) and 31 g/1 dithiothreitol) and 5 μΐ -mercaptoethanol.
The mixtures were boiled for 5 minutes and 10 μΐ aliquots were
applied to the gels. No adjustment was made for individual
Lp(a) concentrations.
Electrotransfer onto nitrocellulose (32), and immunoperoxidase
staining were performed as described (33). In probing the blots,
monoclonal anti-apolipoprotein(a) antibodies cl 280 (IRMA
capturing antibody) and cl 356 (IRMA tracer antibody, both
from Pharmacia Diagnostics AB, Uppsala) were used at final
concentrations of 0.66 mg/1. Biotinylated anti-mouse IgG and
avidin : biotinylated horseradish peroxidase complex were from
Vector Laboratories (Burlingame, CA) and used as recom-
mended by the manufacturer.
Statistics
Linear regression analyses and Wilcoxorfs matched-pairs
signed-ranks test were carried out with SPSSX (release 2.0+ on
UNISYS 1100/91). Non-parametric regression analysis was per-
formed according to Passing & Bablok (34).
Results
Two site immunoradiometric assay (IRMA)
As shown in figure 1, the two monoclonal antibodies
used in the IRMA produced similar, but not identical
immunoblotting patterns. Both antibodies reacted
with the major apolipoprotein(a) isoforms and a large
number of minor bands which are probably due to
proteolytic fragmentation of apolipoprotein(a) (35,
36). Unlike the tracer antibody (cl 356), the solid
phase antibody (cl 280) appeared to react with protein
bands having relative molecular masses of approxi-
mately MT 90 000. In order to study this cross-reac-
tivity without interference from the apolipoprotein(a)
proteolytic fragments, we analysed a sample virtually
lacking Lp(a). In this case, cl 280 detected two bands,
whereas cl 356 detected none (fig. 1, panels c and d).
When purified plasminogen was analysed by immu-
noblotting, an identical pattern was obtained, con-
firming that the capturing antibody of the IRMA
reacted with plasminogen (not shown). We then ex-
amined whether this cross-reactivity could cause com-
' petition of Lp(a) and plaminogen for solid phase sites.
In these studies, purified Lp(a) was mixed with plas-
minogen at different ratios, aiicl Lp(a) was determined
in the mixtures using the IRMA. As shown in figure
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Fig. 1. Immunoblotting of apolipoprotein(a). Detection of apo-
lipoprotein(a) was performed with monoclonal antibod-
ies cl 280 and cl 356. In the IRMA, cl 280 and cl 356
are used as solid phase and detecting antibody, respec-
tively.
Panel a contains analyses in three samples with 340,
420, and 520 U/l Lp(a) (from left to right) probed with
cl 280.
Panel b shows the same samples probed with cl 365.
In panels c and d a so called Lp(a) 'negative' sample
(Lp(a) < 10 U/l) was analysed in duplicate, c was
probed with cl 280, d with cl 365.
The experiments demonstrate that cl 280 (the solid phase
antibody in the IRMA), but not cl 356 (the detecting
antibody) recognized plasminogen.
2, Lp(a) readings decreased in the presence of abnor-
mally high plasminogen concentrations, indicating
that plasminogen can displace Lp(a) from matrix
binding sites. However, up to 800 U/l Lp(a) and 400
mg/1 plasminogen (which is about threefold the nor-
mal concentration) there was no displacement of
Lp(a) from the solid phase.
Intermethod comparison
Figure 3 shows the results of Lp(a) determinations
performed with the three methods in 93 plasma sam-
ples. There was an excellent correlation between the
IRMA and the Lp(a):B-EIA (r = 0.971). Correlation
coefficients were lower between the IRMA and the
0 0.4 0.8 1.2
Plasminogen [g/l]
Fig. 2. IRMA Tor apolipoprotein(a): Interference from plas-
minogen. Purified Lp(a) was mixed with plasminogen
at different ratios, and the mixtures were assayed for
Lp(a) by IRMA (lot No. 28271). In the presence of high
plasminogen concentrations, high Lp(a) concentrations
were underestimated, indicating that plasminogen can
displace Lp(a) from matrix binding sites.
Gray area: normal range for plasminogen.
apo(a)-EIA, and between the Lp(a):B-EIA and the
apo(a)-EIA (0.889 and 0.836, respectively).
Regression lines were calculated using the least
squares method and the non-parametric method pro-
posed by Passing & Bablok (34). For each regression
line, the non-parametric method of Passing & Bablok
resulted in lower absolute values for the intercepts
than the least squares method (tab. 1). Regardless of
whether regression lines were estimated with the least
squares or the non-parametric method, their slopes
consistently indicated that the Lp(a):B-EIA and the
IRMA corresponded well, whereas the apo(a)-EIA
resulted in significantly lower concentrations. This is
also evident if means and medians are compared (tab.
2). The differences between the apo(a)-EIA and the
other methods are striking. The difference between
the Lp(a):B-EIA and the IRMA is smaller, but still
significant when tested with Wilcoxon's matched-pairs
signed-ranks test (p = 0.019).
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Fig. 3. Comparison of two El As and an IRMA for Lp(a). Determinations were carried out in parallel in 93 plasma samples.
Regression lines were estimated using the least squares method (dashed) and the non-parametric method according to
Passing & Bablok (solid). For slopes and intercepts see table 1.
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Tab. 1. Comparison of three immunoassays for Lp(a). Regression lines calculated with the least squares method and with the
non-parametric method according to Passing & Bablok (34).
Method
Lp(a):B-EIA vs IRMA
apo(a)-EIA vs IRMA
apo(a)-EIA vs Lp(a):B-EIA
Least
[mg/1]
a1
1.12
0.42
0.34
squares
b1
-52
29
58
r2
0.971
0.889
0.836
Non-parametric
[mg/1]
a'·3
1.02 (0.94/1.09)
0.54 (0.50/0.60)5
0.54 (0.46/0.62)5
-17
-2
4
(_29/-3)4
(-?/ 4)
(-!/ 14)
1
 a = slope; b = intercept
2
 Pearsons correlation coefficient
3
 in parentheses: lower and upper limits of the 95% confidence intervals as calculated according to Passing & Bablok (34)
4
 intercept significantly different from zero (p < 0.05)
5
 slope significantly different from unity (p < 0.05)
Tab. 2. Comparison of immunoassays for Lp(a) in 93 plasma samples.
Method
IRMA [U/l] '
Lp(a):B-EIA [mg/1]
apo(a)-E!A [mg/1]
Mean
353
344
176
SD
363
420
171
Median
191
142
104
Range
17-1480
17-1748
9- 701
68th percentile
of distances
from the median
192
186
122
Intra-assay and inter-assay CVs are summarized in
tables 3 and 4, respectively. They show that all meth-
ods worked with satisfactory precision.
In an attempt to explain the systematic differences
between the methods, we analysed standards and con-
trols included in the test kits with each of the other
methods, except that the standards used in the IRMA
and the Lp(a):B-EIA were not tested, because they
were provided in a pre-diluted form. Results are
shown in table 5. They show that the assays clearly
differ in their standardization. For instance, when the
calibrator of the apo(a)-EIA was analysed with the
IRMA and with the Lp(a):B-EIA, results were, on
average, 1.5 times and 1.6 times higher than the ex-
Tab. 3. Intra-assay precision (n = 8) of three immunoassays
for the determination of Lp(a).
Method
IRMA [U/l]
sample 1
sample 2
sample 3
,Lp(a):B-EIA [mg/1]
sample 1
sample 2
sample 3
Apo(a)-EIA [mg/1]
sample 1
sample 2
sample 3
Mean
71.1
123.9
552.6
37.1
69.6
358.0
50.6
106.6
264.6
SD
7.0
7.5
16.4
2.6
1.6
8.1
3.1
8.6
14.1
CV
9.85
6.05
2.97
6.95
2.36
2.27
6.18
8.10
5.34
pected values, respectively. This was consistent with
the higher Lp(a) concentrations produced by the
IRMA and the Lp(a):B-EIA, compared with the
apo(a)-EIA.
To determine which of the assays was the most ac-
curate, two highly purified Lp(a) preparations were
analysed with the three methods. The Lp(a) concen-
trations in these preparations were calculated from
their cholesterol content, assuming cholesterol to con-
stitute 44.5% of the Lp(a) particle mass. This resulted
in Lp(a) concentrations of 438 mg/1 and 417 mg/1,
respectively. With the IRMA, we found 1102 mg/1
Tab. 4. Inter-assay precision of three immunoassays for the
determination of Lp(a).
Method Mean SD CV
IRMA [U/l]
Control Low1
Control High1
Lp(a):B-EIA [mg/1]
sample A2
sample B2
sample C2
Apo(a)-EIA [mg/1]
Low Level Control3
High Level Control3
15
15
9
9
9
7
7
129.9
393.8
96.0
363.0
539.7
306.2
414.1
9.0
29.8
5.1
22.2
34.5
24.7
31.2
6.9
7.6
5.3
6.1
6.4
8.1
7.5
a l
 purchased from Pharmacia AB
2
 Because control sera were not available from Byk Sangtec
Diagnostika, frozen plasma samples were used to estimate
the inter-assay precision of the Lp(a):B-EIA.
3
 purchased from Immuno Diagnostika
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Tab. 5. Standardization of Lp(a) immunoassays. Analyses of commercial standards, controls, and of purified Lp(a) with three
different assays.
Material Expected Measured concentrations
tions
 IRMA
IRMA Control High
IRMA Control Low
Apo(a)-EIA Low Level Control
Apo(a)-EIA High Level Control
Apo(a)-EIA calibrator 2
Apo(a)-EIA calibrator 3
Apo(a)-EIA calibrator 4
Apo(a)-EIA calibrator 5
Purified Lp(a) preparation 1
Purified Lp(a) preparation 2
437
132
325
425
70
160
360
700
438
417
382
126
515
661
104
233
496
1125
1102
1087
m/e1
0.87
0.95
1.58
1.56
1.49
1.46
1.38
1.61
2.52
2.61
Lp(a):B-EIA
218
103
569
535
155
288
437
837
760
710
m/e1
0.50
0.78
1.75
1.26
2.21
.80
.21
.20
.74
.70
apo(a)-EIA
165
60
332
467
—
—
—
—460
428
m/e1
0.38
0.45
1.02
1.10
n.d.2
n.d.
n.d.
n.d.
1.05
1.03
Standards and controls provided by the manufacturers of three Lp(a) assays and two different Lp(a) preparations were analysed
with each method. The expected concentrations are those specified by the manufacturer of the respective standard or control. In
the case of purified Lp(a), the expected value was calculated from cholesterol, assuming that cholesterol constitutes 44.5% of the
Lp(a) particle mass.
1
 m/e is the ratio of the measured to the expected concentration. For instance, the Low Control supplied with the IRMA test
kit was specified to contain 132 U/l apolipoprotein(a). When this control was analysed with the Lp(a):B-EIA, 103 mg/1 Lp(a)
were found, and the m/e ratio was 0.78. Data for the calibrators provided with the IRMA and the Lp(a):B-EIA are not
presented because these materials were provided in a pre-diluted form.
2
 n. d. = not determined
and 1087 mg/1 Lp(a) in the two isolates which is more
than 2.6 times greater than the expected concentration
(cf. tab. 5). With the Lp(a):B-EIA, we obtained 760
mg/1 and 710 mg/1 Lp(a) which is 1.7 times more than
expected. Finally, according to the apo(a)-EIA, the
two Lp(a) preparations contained 460 mg/1 and 428
mg/1 Lp(a), respectively. Thus, the IRMA and the
Lp(a):B-EIA considerably overestimated Lp(a),
whereas the apo(a)-EIA was accurately calibrated.
Discussion
We evaluated three commercial methods for the de-
termination of Lp(a): an IRMA, and two non-com-
petitive EIAs. Precision was satisfactory for all meth-
ods. The Lp(a):B-EIA worked with slightly lower CVs
than the other methods.
The apo(a)-EIA yielded markedly lower Lp(a) values
than the IRMA and the Lp(a):B-EIA. The differences
between the methods were attributable to different
calibrations of the assays. Whereas both the IRMA
and the Lp(a):B-EIA overestimated their analyte, the
apo(a)-EIA appeared accurately calibrated when
tested against highly purified Lp(a)i This is in line
with earlier results from our laboratory in which the
specification of ä standard obtained from the manu-
facturer of the apo(a)-EIA was in excellent agreement
with our own estimates (37). According to current
opinion, Lp(a) concentrations above 300 mg/1 are
considered to be associated with a 2—3 fold increase
in coronary risk. If one applies this threshold value
to the current study, 17 out of 93 samples would be
classified differently using either the apo(a)-EIA or
the IRMA (cf. tab. 6). Similarly, 15 out of the 93
samples would be- classified ambiguously with the
apo(a)-EIA or with the Lp(a):B-EIA. This underlines
that a consensus on the standardization of Lp(a)
immunoassays is regardly needed.
Tab. 6. Classification of 93 plasma samples according to Lp(a)
concentrations obtained with different Lp(a) immuno-
assays.
Method
Apo(a)-EIA
Apo(a)-EIA
< 300 mg/1
> 300 mg/1
IRMA
[U/l]
< 300
55
0
Lp(a):B-EIA
[mg/1]
> 300
17
21
< 300
59
2
> 300
13
19
The three assays evaluated in this study differ in their
design and the antibodies used. The IRMA is based
on two monoclonal antibodies. The capturing anti-
body cross-reacts with plasminogen. However, be-
cause the detecting antibody does not recognize plas-
minogen, the assay is specific for Lp(a). Moreover,
we have ruled out the possibility that, under normal
conditions, competition of plasminogen and Lp(a) for
the solid phase resulted in falsely low Lp(a) concen-
trations. Three to four times the normal plasminogen
concentration and high Lp(a) concentrations have to
be present, before any relevant interference occurs.
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 5
300 März et al.: Determination of Lp(a)
The use of monoclonal antibodies in Lp(a) immuno-
assays may entail several problems. More than 20
genetically determined apolipoprotein(a) isoforms
have been described so far. Their relative masses range
from Mr 400000 to Mr 700000. Structurally, apoli-
poprotein(a) isoforms differ by the number of kringle
4 elements, which are homologous, but not identical.
Only one isoform of apolipoprotein(a) containing 37
kringle 4 repeats has been cloned. It is, therefore, not
known which types of kringle 4 are repeated or
whether some of them are missing in smaller apoli-
poprotein(a) isoforms. Furthermore, there may be
sequence heterogeneity in kringle 5 or the protease
domain. Thus, it is conceivable that certain apolipo-
protein(a) isoforms are not recognized by monoclonal
antibodies. However, these considerations do obvi-
ously not apply to the IRMA used in this study. First,
the good correlation between the IRMA and the
Lp(a):B-EI^ makes it unlikely that one of the two
assays fails to recognize a particular apolipoprotein(a)
isoform. Second, among 93 samples studied none was
found which gave a substantially lower signal in the
IRMA (two monoclonal antibodies) than in the
apo(a)-EIA (two polyclonal antibodies). Third, when
antibodies cl 280 and cl 356 were used in immuno-
blotting experiments with different plasma samples
they produced patterns identical to those obtained
with polyclonal antisera (März, W., unpublished).
In this study, the Lp(a):B-EIA correlated better with
the IRMA than the apo(a)-EIA. Most likely this is
due to differences in design of the EIAs. The apo(a)-
EIA uses the same polyclonal anti-apolipoprotein(a)
as tracer and as capturing antibody. Strictly speaking,
this assay measures apolipoprotein(a) mass concen-
tration. Hence it may be influenced by the apolipo-
protein(a) genetic polymorphism. Beyond this poly-
morphism, there is a tremendous intra-individual het-
erogeneity of lipoprotein(a) particles (35). It is, there-
fore, not very likely that apolipoprotein(a) can be
measured on a molar basis, when only polyclonal
anti-apolipoprotein(a) is used. In contrast, because it
is suggested that there is one molecule of apolipopro-
tein B per Lp(a) particle, the Lp(a):B-EIA will reflect
the molar concentration of intact Lp(a):B complexes,
irrespective of the apolipoprotein(a) isoform. A po-
tential drawback of assays using anti-apolipoprotein
B as detecting antibody is that Lp(a) may be over-
estimated due to the presence of complexes between
Lp(a) and LDL (38, 39). HoWever, in solid phase
immunoassays, this may not be a major problem,
because incubations are performed in the presence of
non-ionic detergents which may dissociate Lp(a)-LDL
complexes.
As mentioned before, the IRMA excellently correlated
with the Lp(a):B-EIA. This suggests that not only the
Lp(a):B-EIA, but also the IRMA estimated Lp(a):B
particle concentration rather than apolipoprotein(a)
mass concentration. Since two monoclonal antibodies
for apolipoprotein(a) are used in the IRMA, the tracer
antibody must recognize an epitope present once per
apolipoprotein(a) molecule. Such an epitope is more
likely to be located in kringle 5 or the protease-like
domain of apolipoprotein(a) than in the repetitive
kringle 4. As a consequence, the IRMA should be
insensitive to variations in the number of kringle 4
repeats, i. e. apolipoprotein(a) size polymorphism.
In summary, these data show that there are still many
unresolved problems concerning the measurement of
Lp(a). Design and antibodies have strong impacts on
Lp(a) assays. Methods reflecting particle concentra-
tion such as the IRMA or the Lp(a):B-EIA are insen-
sitive to apolipoprotein(a) heterogeneity. In solid
phase binding assays using anti-apolipoprotein(a) as
capturing antibody and anti-apolipoprotein B as de-
tecting antibody, cross^reactivity with plasminogen is
not a major concern. In further attempts to standard-
ize the measurement of Lp(a), major efforts should
therefore be devoted to this type of assay. As results
of Lp(a) assays may differ by more than 100% these
attempts should be made soon.
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Note added in proof
On the basis of the results presented in this article, the calibra-
tion of the Lp(a):B-EIA will be revised by the manufacturer.
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